---
title: "JW THERAP-B Plans to Issue Approximately 61.1855 Million Subscription Shares at a Discount of About 2.97% to Raise HK$160 Million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305571631.md"
description: "JW THERAP-B announced that it has entered into subscription agreements with China Hongqiao and Novo Vista to issue approximately 61.1855 million shares at HK$2.615 per share (representing a discount of approximately 2.97% to the market price), raising HK$160 million. The net proceeds will be used to advance the R&D of its CAR-T product pipeline, support clinical studies of autologous CAR-T therapies, upgrade its technology platform and manufacturing capabilities, and supplement working capital"
datetime: "2026-11-15T12:07:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305571631.md)
  - [en](https://longbridge.com/en/news/305571631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305571631.md)
generator: "portal-rs"
---

# JW THERAP-B Plans to Issue Approximately 61.1855 Million Subscription Shares at a Discount of About 2.97% to Raise HK$160 Million

Zhitong Finance APP reports: JW THERAP-B (02126) announced that on November 15, 2026, the company entered into subscription agreements with China Hongqiao Holdings Limited or its designated entities and Novo Vista Limited Partnership. It plans to issue a total of approximately 61.1855 million subscription shares to them at HK$2.615 per share. This price represents a discount of approximately 2.97% compared to the closing price of HK$2.695 per share quoted on the Stock Exchange of Hong Kong on the last trading day. The total subscription amount is HK$160 million.

The company intends to use the net proceeds from the subscription for the following purposes: approximately 40% will be used to advance the R&D of the group's in vivo CAR-T product pipeline (including JWCAR306 and other candidate products), covering investigator-initiated trials (IIT), manufacturing process development and optimization, IND-enabling studies, and other related R&D activities; approximately 30% will be used to support the R&D of the group's autologous CAR-T product pipeline (including JWCAR201 and JWCAR239, a dual-target, dual-armored CD19/CD20 CAR-T candidate product), focusing on advancing ongoing and planned clinical studies, generating clinical data, conducting IND-enabling studies, and optimizing manufacturing processes; approximately 20% will be used to support the continuous development and upgrading of the group's technology platform and manufacturing capabilities, including the purchase, replacement, and upgrading of manufacturing and laboratory equipment, as well as improvements to existing manufacturing facilities and related infrastructure; and approximately 10% will be used to support the group's working capital needs and general corporate purposes.

### Related Stocks

- [02126.HK](https://longbridge.com/en/quote/02126.HK.md)
- [01378.HK](https://longbridge.com/en/quote/01378.HK.md)

## Related News & Research

- [JW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO Says](https://longbridge.com/en/news/305657382.md)
- [JW Therapeutics Plans Presentation on Carteyva® NRDL Inclusion](https://longbridge.com/en/news/305580658.md)
- [JW Therapeutics Expects Carteyva Unit Manufacturing Costs to Fall More Than 65%](https://longbridge.com/en/news/305568923.md)
- [Carteyva Included in 2026 National Reimbursement Drug List](https://longbridge.com/en/news/305580213.md)
- [China adds first CAR-T cancer therapy to national health insurance scheme](https://longbridge.com/en/news/305521334.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**